Avacta Group PLC tapped Eliot Forster to replace Trevor Nichols as the nonexecutive chairman of the London-listed biotechnology company's board.
Nichols, who has acted as chairman since January 2014, will remain with the company as a nonexecutive director.
Forster has more than 25 years of experience in the pharmaceutical and biotechnology industry and most recently served as the CEO of Immunocore Ltd. where he helped raise over £230 million in funding, Avacta said in a statement.
At Immunocore, a company focused on developing treatments for cancer, Forster also helped secure partnerships with AstraZeneca PLC, one of the largest pharmaceutical companies in the world, and the Bill & Melinda Gates Foundation.
At Avacta, Nichols is expected to assist the company as it advances its proprietary pipeline of therapeutic products, which include potential treatments for cancer and bleeding disorders.
